All Posts
  • Interviews
1 min read

Graphite Bio co-founder debuts Treg cell therapy startup with $75M, aims to ‘trick’ immune system into resetting

On this page

Share

Tr1x launched from stealth Wednesday with $75 million to tackle graft-versus-host disease in addition to inflammatory and autoimmune conditions.

Related Articles

Explore posts connected to this topic

View Resources

Bag of Tr1Xs: Off-the-Shelf Type 1 Treg Shows Phase I Promise for GvHD

In a clinical first, Tr1X Bio showed immune reconstitution and engraftment for allogeneic Tr1 cell therapy, establishing clinical safety and...

  • Interviews

Tr1X Presents First Clinical Data Demonstrating Proof of Safety and Proof of Mechanism With Allogeneic Off-the-Shelf Tr1 Regulatory T Cell Therapy TRX103

First clinical data from Phase 1 dose-escalation study in patients

  • Press Releases

The BioHub Podcast with David de Vries, Co-Founder, CEO, discussing Tr1X’s pipeline of Type-1 regulatory T cells

The BioHub Podcast with David de Vries, Co-Founder, CEO, discussing

  • Videos

In a clinical first, Tr1X Bio showed immune reconstitution and

  • Interviews

First clinical data from Phase 1 dose-escalation study in patients

  • Press Releases

The BioHub Podcast with David de Vries, Co-Founder, CEO, discussing

  • Videos